{"doi":"10.1128/jvi.02350-20","title":"A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity","abstract":"Despite advances in antiretroviral therapy, HIV remains a global epidemic and has claimed more than 32 million lives. Accordingly, developing an effective HIV vaccine remains an urgent public health need. The gp41 N-heptad repeat (NHR) of the HIV-1 prehairpin intermediate (PHI) is highly conserved (>90%) and is inhibited by the FDA-approved drug enfuvirtide, making it an attractive vaccine target. However, to date, anti-NHR antibodies have not been potent. Here, we engineered D5_AR, a more potent variant of the anti-NHR antibody D5, and established its ability to inhibit HIV-1 strains that are more difficult to neutralize and are more representative of circulating strains (tier-2 strains). The neutralizing activity of D5_AR was greatly potentiated in cells expressing FcγRI; FcγRI is expressed on cells that are implicated at the earliest stages of sexual HIV-1 transmission. Taken together, these results bolster efforts to target the gp41 NHR and the PHI for vaccine development.","journal":"Journal of Virology","year":2021,"id":189972,"datarank":0.584120115673885,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.17791258550855346,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.17791258550855346,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":5,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9551,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":567705,"name":"Maria V. Filsinger Interrante","orcid":"0000-0002-7728-799X","position":1,"is_corresponding":false},{"id":567706,"name":"Benjamin N. Bell","orcid":"0000-0001-5356-0173","position":2,"is_corresponding":false},{"id":569290,"name":"Clayton L. Brown","orcid":null,"position":3,"is_corresponding":false},{"id":753426,"name":"Theodora U. J. Bruun","orcid":"0000-0002-7462-2537","position":4,"is_corresponding":false},{"id":103753,"name":"Celia C. LaBranche","orcid":"0000-0002-6653-6655","position":5,"is_corresponding":false},{"id":103755,"name":"David C. Montefiori","orcid":"0000-0003-0856-6319","position":6,"is_corresponding":false},{"id":226842,"name":"Peter S. Kim","orcid":"0000-0001-6503-4541","position":7,"is_corresponding":false},{"id":567707,"name":"Adonis A. Rubio","orcid":"0000-0003-3676-4283","position":0,"is_corresponding":true}],"reference_count":133,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T23:49:22.671571Z","pmid":"33980592","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}